Navigation Links
invivodata Certified to Deliver EXACT in COPD Trials
Date:4/23/2009

PITTSBURGH, April 23 /PRNewswire/ -- invivodata inc., the industry leader in electronic Patient-Reported Outcomes (ePRO) solutions and services for global clinical research, today announced that it has completed a certification program to provide the EXAcerbations of Chronic pulmonary disease Tool (EXACT) on its DiaryPRO(C) field-based ePRO system.

The EXACT is a Patient-Reported Outcome (PRO) measure for evaluating the frequency, severity, and duration of acute exacerbations of chronic obstructive pulmonary disease (COPD) and chronic bronchitis (AECB) in international clinical trials. Developed by United BioSource Corporation's (UBC) Center for Health Outcomes Research, with significant input from clinical and instrument development experts and involvement of the U.S. Food and Drug Administration (FDA), the EXACT is the industry's only standardized tool for measuring exacerbations of COPD.

"Being a certified provider of this unique tool enables us to offer our global customers a reliable and efficient means of implementing the EXACT in their clinical trials as they develop more effective COPD treatments," said Tom Henson, invivodata vice president of marketing.

COPD, which includes chronic bronchitis and emphysema, is a disease characterized by obstruction to airflow that interferes with normal breathing. COPD is the fourth leading cause of death in the world, and further increases in the prevalence and mortality of the disease are predicted in the coming decades (Source: www.who.int). In the United States 11.4 million Americans are diagnosed with the disease with over 122,000 deaths each year. Clinical researchers have put significant effort into developing new COPD treatments, as evidenced by the 33% increase in clinical trials for new COPD medications since 2006 (Source: www.clinicaltrials.gov).

"We are pleased to certify invivodata on the electronic delivery of the EXACT and to continue our work with them in assuring high quality data in all types of clinical studies in which the instrument is used," said Dr. Nancy Kline Leidy, senior vice president of scientific affairs for UBC and Principal Investigator of the EXACT-PRO Initiative. "We have found their e-diary device meets the needs of the EXACT and is ready for use in international trials."

Licensing agreements to use the EXACT are obtained directly from United BioSource Corporation.

About invivodata inc.

invivodata combines behavioral science, information technology, and clinical research expertise to capture high quality clinical trial data directly from patients. invivodata's electronic Patient-Reported Outcomes (ePRO) solutions, which are based on over 20 years of research, deliver reliable patient self-reported data by driving patient compliance with the protocol and eliminating recall biases that plague paper-based self-report data. invivodata's solutions include comprehensive trial-support services that facilitate the collection of ePRO data, web-based access to study data and operational reports that give researchers and sponsors visibility into study progress, and scientific and regulatory consulting on the use of PRO data in a regulated environment. invivodata's solution has been used in more than 275 clinical programs and is the industry-leading ePRO system in delivering primary efficacy data for FDA drug approvals. invivodata inc. is a privately held company with global headquarters in Pittsburgh, Pa., USA; its European headquarters is in London, England; and its technology development center is in Scotts Valley, Calif., USA. For more information visit www.invivodata.com.

About United BioSource Corporation

United BioSource Corporation delivers science-based solutions to support the development and commercialization of pharmaceuticals, biotechnology, and medical devices. The company leverages a unique suite of scientific and strategic capabilities to demonstrate product effectiveness and safety, manage and minimize risk, document economic value, and secure appropriate third-party payment for prescription medicines and other medical technology. UBC's global operations are managed by research scientists and industry experts in offices throughout North America and Europe. The company is headquartered in Bethesda, Maryland. For more information, please visit www.unitedbiosource.com.

    For more information, contact:

    invivodata inc.
    Christine Tobin
    Corporate Communications Specialist
    (412) 390-3000, ext. 3502
    ctobin@invivodata.com


'/>"/>
SOURCE invivodata inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. invivodata Captures Symptom Relief Data in Endometriosis Trial
2. MedNet Solutions Certified to Score SF-12v2 Health Survey
3. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
4. Argonauta Communications Certified as Women-Owned Business by the Womens Business Enterprise National Council (WBENC)
5. Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance
6. New Study Suggests Rx Estrogen Delivery Through the Skin May Show Safety Benefits as Opposed to Oral Delivery
7. Michael J. Fox Foundation Awards $2.1 Million to Improve Drug Delivery in Parkinsons Disease
8. DSM Obtains Exclusive World-Wide License for Innovative Drug Delivery Technology
9. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
10. Reproductive Partners Participates in New IVF Progesterone Delivery System Study
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):